Iga Swiatek, a five-time Grand Slam champion, has accepted a one-month suspension following a positive test for a prohibited substance in August.
The International Tennis Integrity Association has accepted her explanation that the results were unintentional. The substance in question was a heart medication referred to as T-M-Z, which Swiatek indicated was contaminated due to the use of melatonin to address jet lag. She was provisionally suspended in September and, as a result, missed three tournaments. Currently, she has eight days remaining in her suspension.
“The WTA acknowledges the decision by the International Tennis Integrity Association (ITIA) – which administers the Tennis Anti-Doping Program (TADP) – in issuing a one-month suspension to Iga Swiatek,” WTA said in a statement. “Following the identification of a contaminated regulated medication (melatonin) as the source for her positive test for the prohibited substance Trimetazidine.”
Iga Swiatek dominates in Miami Open final first Polish tennis player ranked No.1
“The WTA fully supports Iga during this difficult time,” WTA added. “Iga has consistently demonstrated a strong commitment to fair play and upholding the principles of clean sport, and this unfortunate incident highlights the challenges athletes face in navigating the use of medications and supplements.”
“The WTA remains steadfast in our support for a clean sport and the rigorous processes that protect the integrity of competition,” WTA added. “We also emphasize that athletes must take every precaution to verify the safety and compliance of all products they use, as even unintentional exposure to prohibited substances can have significant consequences.”
“We will continue to work closely with our athletes to provide education and resources that empower athletes to make informed decisions and maintain the highest standards of integrity in our sport,” WTA concluded.
Photo/IgaSwiatek/X
WTA contributed to this column
One thought